XERS PDUFA decision: a positive outcome, -6.6%

On September 10, 2019, Xeris Biopharma Holdings, Inc. reached its PDUFA decision. The result was a positive outcome, and the stock moved -6.6% in the window around the event. It had already run -11.3% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.